23.85
1.72 (7.77%)
| Penutupan Terdahulu | 22.13 |
| Buka | 22.01 |
| Jumlah Dagangan | 1,178,982 |
| Purata Dagangan (3B) | 1,353,056 |
| Modal Pasaran | 2,605,608,192 |
| Harga / Pendapatan (P/E TTM) | 9.81 |
| Harga / Jualan (P/S) | 64.99 |
| Harga / Buku (P/B) | 6.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Oct 2026 |
| Margin Operasi (TTM) | -340.67% |
| EPS Cair (TTM) | -2.60 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.54% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -191.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -106.56 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Nurix Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.75 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.41% |
| % Dimiliki oleh Institusi | 111.85% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 22.99 | -5,786 | -133,020 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,786 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -133,020 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 22.99 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | Pegawai | 02 Oct 2026 | Jual automatik (-) | 5,786 | 22.99 | 133,020 |
| RING CHRISTINE | Pegawai | 02 Oct 2026 | Pelaksanaan pilihan | 5,786 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |